These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 23315167

  • 21. Combining gene therapy and fetal hemoglobin induction for treatment of β-thalassemia.
    Breda L, Rivella S, Zuccato C, Gambari R.
    Expert Rev Hematol; 2013 Jun; 6(3):255-64. PubMed ID: 23782080
    [Abstract] [Full Text] [Related]

  • 22. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K, Jain D, Gattani S, Jijina F, Nadkarni A, Sawant P, Nair S, Mohanty D, Ghosh K, Colah R.
    Blood Cells Mol Dis; 2009 Jun; 42(1):25-31. PubMed ID: 18954999
    [Abstract] [Full Text] [Related]

  • 23. The therapeutic reactivation of fetal haemoglobin.
    Olivieri NF, Weatherall DJ.
    Hum Mol Genet; 1998 Jun; 7(10):1655-8. PubMed ID: 9735388
    [Abstract] [Full Text] [Related]

  • 24. Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia.
    Walker AL, Steward S, Howard TA, Mortier N, Smeltzer M, Wang YD, Ware RE.
    Blood; 2011 Nov 17; 118(20):5664-70. PubMed ID: 21921042
    [Abstract] [Full Text] [Related]

  • 25. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
    Rigano P, Pecoraro A, Calvaruso G, Steinberg MH, Iannello S, Maggio A.
    Am J Hematol; 2013 Nov 17; 88(11):E261-4. PubMed ID: 23828131
    [Abstract] [Full Text] [Related]

  • 26. Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease.
    Green NS, Barral S.
    Pediatr Blood Cancer; 2011 Feb 17; 56(2):177-81. PubMed ID: 20830771
    [Abstract] [Full Text] [Related]

  • 27. Hydroxyurea and sickle cell disease: a chance for every patient.
    Weiner DL, Brugnara C.
    JAMA; 2003 Apr 02; 289(13):1692-4. PubMed ID: 12672739
    [No Abstract] [Full Text] [Related]

  • 28. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells.
    Moutouh-de Parseval LA, Verhelle D, Glezer E, Jensen-Pergakes K, Ferguson GD, Corral LG, Morris CL, Muller G, Brady H, Chan K.
    J Clin Invest; 2008 Jan 02; 118(1):248-58. PubMed ID: 18064299
    [Abstract] [Full Text] [Related]

  • 29. Induction of fetal hemoglobin in the treatment of sickle cell disease.
    Fathallah H, Atweh GF.
    Hematology Am Soc Hematol Educ Program; 2006 Jan 02; ():58-62. PubMed ID: 17124041
    [Abstract] [Full Text] [Related]

  • 30. Hemoglobin switching protocols in thalassemia. Experience with sodium phenylbutyrate and hydroxyurea.
    Dover GJ.
    Ann N Y Acad Sci; 1998 Jun 30; 850():80-6. PubMed ID: 9668530
    [Abstract] [Full Text] [Related]

  • 31. Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease.
    Hoppe C, Vichinsky E, Quirolo K, van Warmerdam J, Allen K, Styles L.
    J Pediatr Hematol Oncol; 2000 Jun 30; 22(4):330-4. PubMed ID: 10959903
    [Abstract] [Full Text] [Related]

  • 32. Hydroxyurea and fetal hemoglobin effect on leg ulcers in patients with sickle cell disease.
    Tolu SS, Crouch A, Choi J, Gao Q, Reyes-Gil M, Ogu UO, Vinces G, Minniti CP.
    Ann Hematol; 2022 Mar 30; 101(3):541-548. PubMed ID: 35039901
    [Abstract] [Full Text] [Related]

  • 33. Genomic variants in members of the Krüppel-like factor gene family are associated with disease severity and hydroxyurea treatment efficacy in β-hemoglobinopathies patients.
    Stratopoulos A, Kolliopoulou A, Karamperis K, John A, Kydonopoulou K, Esftathiou G, Sgourou A, Kourakli A, Vlachaki E, Chalkia P, Theodoridou S, Papadakis MN, Gerou S, Symeonidis A, Katsila T, Ali BR, Papachatzopoulou A, Patrinos GP.
    Pharmacogenomics; 2019 Jul 30; 20(11):791-801. PubMed ID: 31393228
    [Abstract] [Full Text] [Related]

  • 34. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
    Charache S.
    Semin Hematol; 1997 Jul 30; 34(3 Suppl 3):15-21. PubMed ID: 9317197
    [Abstract] [Full Text] [Related]

  • 35. Fetal hemoglobin regulation in β-thalassemia: heterogeneity, modifiers and therapeutic approaches.
    Sripichai O, Fucharoen S.
    Expert Rev Hematol; 2016 Dec 30; 9(12):1129-1137. PubMed ID: 27801605
    [Abstract] [Full Text] [Related]

  • 36. Pharmacological induction of fetal hemoglobin: Why haven't we been more successful in thalassemia?
    Fathallah H, Sutton M, Atweh GF.
    Ann N Y Acad Sci; 2005 Dec 30; 1054():228-37. PubMed ID: 16339670
    [Abstract] [Full Text] [Related]

  • 37. Long-term use of hydroxyurea for sickle cell anemia.
    Hagar W.
    JAMA; 2003 Aug 13; 290(6):753; author reply 754. PubMed ID: 12915424
    [No Abstract] [Full Text] [Related]

  • 38. Hydroxyurea, sickle cell disease and renal transplantation.
    Allen A, Scoble J, Snowden S, Hambley H, Bellingham A.
    Nephron; 1997 Aug 13; 75(1):106-7. PubMed ID: 9031282
    [No Abstract] [Full Text] [Related]

  • 39. Hydroxyurea in children: present and future.
    Vichinsky EP.
    Semin Hematol; 1997 Jul 13; 34(3 Suppl 3):22-9. PubMed ID: 9317198
    [Abstract] [Full Text] [Related]

  • 40. Physiologic decline in fetal hemoglobin parameters in infants with sickle cell disease: implications for pharmacological intervention.
    Marcus SJ, Ware RE.
    J Pediatr Hematol Oncol; 1999 Jul 13; 21(5):407-11. PubMed ID: 10524455
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.